Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Abstract Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was first approved for the treatment of Non-Hodgkin’s Lymphoma. Monoclonal antibodies against cancer antigens have been successful strategies for only a handful of cancer types due to many reasons includ...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2018-09-01
|
| Rangatū: | Molecular Medicine |
| Ngā marau: | |
| Urunga tuihono: | http://link.springer.com/article/10.1186/s10020-018-0051-4 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|